YK012
/ Excyte
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
November 19, 2025
A Phase I Study of YK012 in Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=66 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd
New P1 trial • Glomerulonephritis • Renal Disease
August 18, 2025
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1/2 | N=189 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd | N=144 ➔ 189
Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
June 09, 2025
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1/2 | N=144 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd
New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
May 21, 2025
Study of YK012 in Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Excyte Biopharma Ltd
New P1 trial • Glomerulonephritis • Renal Disease
August 30, 2024
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1/2 | N=46 | Recruiting | Sponsor: Excyte Biopharma Ltd
New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
August 22, 2024
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Excyte Biopharma Ltd
New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 6
Of
6
Go to page
1